Relationship between disorders of the intestinal microbiota and heart failure in infants with congenital heart disease

Zhang, Qiliang; Chen, Xiuhua; Zhou, Si-Jia; Lei, Yu-Qing; Huang, Jing; Chen, Qiang; Cao, Hua

doi:10.3389/fcimb.2023.1152349

Cited by 6 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disordered intestinal microbiota in HF patients is mainly characterized by an increase in pathogenic bacteria and a decrease in beneficial bacteria, which aggravate the intestinal inflammatory reaction and increase the levels of intestinal inflammatory factors and toxin secretion [ 16 – 18 ]. Our previous study revealed that heart failure in infants with congenital heart disease dysregulated the intestinal microbiota, which was characterized by an increase in pathogenic bacteria, a decrease in beneficial bacteria, and decreases in diversity and richness [ 19 ]. This study further examined the relationship between heart failure and intestinal inflammation in infants with CHD.…”

Section: Discussionmentioning

confidence: 99%

Relationship between heart failure and intestinal inflammation in infants with congenital heart disease

Zhang,

Chen,

Zhou

et al. 2024

BMC Microbiol

Self Cite

View full text Add to dashboard Cite

Objective The association between heart failure (HF) and intestinal inflammation caused by a disturbed intestinal microbiota in infants with congenital heart disease (CHD) was investigated. Methods Twenty infants with HF and CHD who were admitted to our hospital between October 2021 and March 2022 were included in this study. Twenty age- and sex-matched infants without HF at our hospital were selected as the control group. Faecal samples were obtained from each participant and analysed by enzyme-linked immunoassay and 16 S rDNA sequencing to assess intestinal inflammatory factors and the microbiota. Results The levels of intestinal inflammatory factors, including IL-1β, IL-4, IL-6, IL-17 A and TNF-α, were greatly increased, while the levels of IL-10 were significantly decreased in the HF group compared to the control group (p < 0.05). The intestinal microbial diversity of patients in the HF group was markedly lower than that in the control group (p < 0.05). The abundance of Enterococcus was significantly increased in the HF group compared to the control group (p < 0.05), but the abundance of Bifidobacterium was significantly decreased in the HF group compared to the control group (p < 0.05). The diversity of the intestinal microbiota was negatively correlated with the levels of IL-1β, IL-4, IL-6 and TNF-α in the intestinal tract but was positively correlated with that of IL-10. The abundance of Enterococcus was positively associated with the levels of IL-1β, IL-4, IL-6 and TNF-α in the intestinal tract but was negatively correlated with that of IL-10. NT-proBNP was positively associated with the levels of IL-1β, IL-4, IL-6 and TNF-α in the HF group but was negatively correlated with that of IL-10. The heart function score was positively associated with the levels of IL-1β, IL-4, IL-6 and TNF-α in the HF group but was negatively correlated with that of IL-10. Conclusions Infants with CHD-related HF had a disordered intestinal microbiota, decreased diversity of intestinal microbes, increased levels of pathogenic bacteria and decreased levels of beneficial bacteria. The increased abundance of Enterococcus and the significant decrease in the diversity of the intestinal microbiota may exacerbate the intestinal inflammatory response, which may be associated with the progression of HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship between heart failure and intestinal inflammation in infants with congenital heart disease

Zhang,

Chen,

Zhou

et al. 2024

BMC Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

“… 30 Furthermore, another study observed similar characteristics in the gut microbiota of CHD- HF patients compared to CCHD, with a significant increase in Enterococcus abundance and a decrease in Bifidobacteriaceae abundance compared to the control group. 31 These findings suggest that when there is severe impairment of cardiac function in young children, the intestines may experience ischemia or congestion, leading to reduced oxygen supply, increased acidity in the intestinal microenvironment, 32 and thus leading to distinct alterations in the gut microbiota.…”

Section: From Birth To Infantmentioning

confidence: 99%

“… Stage High incidence age CVDs Characteristics of gut bacteria Study object Ref. From birth to infant 0 year old CHD Bifidobacteriaceae, Lactobacillus ↓ CHD mothers 27 Bifidobacteriaceae ↓ Enterococcus ↑ CCHD patients 30 Enterococcus ↑ Bifidobacteriaceae ↓ CHD-HF patients 31 Child and adolescent ≤5 KD Lachnospiracea _ incertae _ sedis , Bacteroides , Blautia ↓ Escherichia _ Shigella , Bifidobacterium , Enterococcus ↑ KD patients 63 Fecal bacillus , Roseburia ↓ KD patients 64 5–18 years old T1DM Streptococcus thermophilus and Lactococcus lactis ↓ Bifidobacteriaceae ↑ T1DM pre onset patients 71 Actinobacteria , Firmicutes ↓ Bacteroidaceae ↑ Lactobacillus , Bifidobacterium , Blautia cocoides / Euberium rectale group, Prevotella ↓ Clostridium , Bacteroide...…”

Section: Future Perspectivesmentioning

confidence: 99%

Advancing lifelong precision medicine for cardiovascular diseases through gut microbiota modulation

Shi,

Li,

2024

Gut Microbes

View full text Add to dashboard Cite

The gut microbiome is known as the tenth system of the human body that plays a vital role in the intersection between health and disease. The considerable inter-individual variability in gut microbiota poses both challenges and great prospects in promoting precision medicine in cardiovascular diseases (CVDs). In this review, based on the development, evolution, and influencing factors of gut microbiota in a full life circle, we summarized the recent advances on the characteristic alteration in gut microbiota in CVDs throughout different life stages, and depicted their pathological links in mechanism, as well as the highlight achievements of targeting gut microbiota in CVDs prevention, diagnosis and treatment. Personalized strategies could be tailored according to gut microbiota characteristics in different life stages, including gut microbiota-blood metabolites combined prediction and diagnosis, dietary interventions, lifestyle improvements, probiotic or prebiotic supplements. However, to fulfill the promise of a lifelong cardiovascular health, more mechanism studies should progress from correlation to causality and decipher novel mechanisms linking specific microbes and CVDs. It is also promising to use the burgeoning artificial intelligence and machine learning to target gut microbiota for developing diagnosis system and screening for new therapeutic interventions.

show abstract

“…The decreased composition of certain probiotics may affect fetal development through impaired gut barrier, chronic inflammation, and insulin resistance [ 61 ]. The disorder of gut microbiome and metabolism was observed in patients with CHD and heart failure, which was characterized by decreasing microbiome diversity, richness, and downregulation of retinol metabolism [ 62 ]. The serum level of bile acids in patients with repaired Tetralogy of Fallot (TOF) has a positive correlation with indexed right ventricular end‐diastolic volume, which may suggest impaired liver function due to right ventricular dysfunction and systemic congestion [ 63 ].…”

Section: Microbiome Metabolites and Cardiovascular Diseasesmentioning

confidence: 99%

From heart to gut: Exploring the gut microbiome in congenital heart disease

Liu,

Huang,

et al. 2023

iMeta

View full text Add to dashboard Cite

Congenital heart disease (CHD) is a prevalent birth defect and a significant contributor to childhood mortality. The major characteristics of CHD include cardiovascular malformations and hemodynamical disorders. However, the impact of CHD extends beyond the circulatory system. Evidence has identified dysbiosis of the gut microbiome in patients with CHD. Chronic hypoxia and inflammation associated with CHD affect the gut microbiome, leading to alterations in its number, abundance, and composition. The gut microbiome, aside from providing essential nutrients, engages in direct interactions with the host immune system and indirect interactions via metabolites. The abnormal gut microbiome or its products can translocate into the bloodstream through an impaired gut barrier, leading to an inflammatory state. Metabolites of the gut microbiome, such as short‐chain fatty acids and trimethylamine N‐oxide, also play important roles in the development, treatment, and prognosis of CHD. This review discusses the role of the gut microbiome in immunity, gut barrier, neurodevelopment, and perioperative period in CHD. By fostering a better understanding of the cross‐talk between CHD and the gut microbiome, this review aims to contribute to improve clinical management and outcomes for CHD patients.

show abstract

Relationship between disorders of the intestinal microbiota and heart failure in infants with congenital heart disease

Cited by 6 publications

References 32 publications

Relationship between heart failure and intestinal inflammation in infants with congenital heart disease

Relationship between heart failure and intestinal inflammation in infants with congenital heart disease

Advancing lifelong precision medicine for cardiovascular diseases through gut microbiota modulation

From heart to gut: Exploring the gut microbiome in congenital heart disease

Contact Info

Product

Resources

About